Global /United States /Healthcare /Drug Manufacturers - General /CRBP

Corbus Pharmaceuticals Holdings, Inc.

CRBP

• NASDAQ: CRBP • Delayed

9.82USD 0%

As of 14 June 2026, Corbus Pharmaceuticals Holdings, Inc. has a market cap of $174.17M USD, ranking #21934 globally and #3543 in the United States. It ranks #1972 in the Healthcare sector, and #710 in the Drug Manufacturers - General industry.

Global Rank

21934

Country Rank

3543

Sector Rank

1972

Industry Rank

710

Key Stats

Market Cap

$174.17MUSD

Enterprise Value

$15.73MUSD

EBITDA (TTM)

-$85.08MUSD

Net Income (TTM)

-$78.54MUSD

PB Ratio

1.2

Company Profile

Country (HQ)

United States

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Yuval Cohen open_in_new

Employees

Founded

2009

Website

corbuspharma.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0%	-6.3%	13%	13%	-43%	21%	31%	12%	-83%

News

CRBP Analyst Forecasts

Markets

Exchange	Ticker	Price	Quotes
NASDAQ MIC: XNAS PRIMARY	CRBP Corbus Pharmaceuticals Holdings Inc ISIN: US21833P3010 Shares Out.: Shares Outstanding: 18.528M¹ Shares Float: 16.62M² TV: TradingView: NASDAQ: CRBP SA: Stock Analysis: NASDAQ: CRBP YF: Yahoo Finance: CRBP GF: Google Finance: NASDAQ: CRBP NQ: NASDAQ: CRBP BA: Barron's: CRBP MS: Morningstar: XNAS: CRBP	9.82 USD	TV: TradingView: NASDAQ: CRBP SA: Stock Analysis: NASDAQ: CRBP YF: Yahoo Finance: CRBP GF: Google Finance: NASDAQ: CRBP NQ: NASDAQ: CRBP BA: Barron's: CRBP MS: Morningstar: XNAS: CRBP
London Stock Exchange (LSE / LON) MIC: XLON	0SZI Corbus Pharmaceuticals Holdings Inc ISIN: US21833P3010 TV: TradingView: LSE: 0SZI SA: Stock Analysis: LON: 0SZI YF: Yahoo Finance: 0SZI.L GF: Google Finance: LON: 0SZI BA: Barron's: 0SZI MS: Morningstar: XLON: 0SZI	9.89 USD	TV: TradingView: LSE: 0SZI SA: Stock Analysis: LON: 0SZI YF: Yahoo Finance: 0SZI.L GF: Google Finance: LON: 0SZI BA: Barron's: 0SZI MS: Morningstar: XLON: 0SZI

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Corbus Pharmaceuticals Holdings, Inc.

Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.

Similar Companies

Industry: Drug Manufacturers - General (United States)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 437K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 314K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 207K%	97.4	United States
Merck & Co., Inc. NYSE: MRK	$274.03B 157K%	15.1	United States
Pfizer Inc. NYSE: PFE	$149.38B 86K%	19.5	United States
Bristol-Myers Squibb Co. NYSE: BMY	$117.58B 67K%	16.8	United States

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Roche Holding AG SIX: RO	$321.52B 256.25B CHF 184K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$288.84B 215.59B GBP 166K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$274.65B 218.9B CHF 158K%	20.5	Switzerland
Novo Nordisk A/S CPH: NOVO-B	$181.82B 1.18T DKK 104K%	11.5	Denmark
Sanofi EPA: SAN	$110.1B 95.26B EUR 63K%	19.9	France
GSK plc LSE: GSK	$108.46B 80.96B GBP 62K%	14.6	United Kingdom

chevron_leftBack